Ascendis Pharma A/s

Ascendis Pharma A/S reports a Form 4 filing detailing the acquisition of ordinary shares by EVP & Chief Financial Officer, Scott Thomas Smith.

Jean Jacques Bienaime, a Director at Ascendis Pharma A/S, reported transactions involving the acquisition of ordinary shares on May 29, 2026.

Ascendis Pharma A/S reports an acquisition of ordinary shares by its EVP & Chief Financial Officer, Scott Thomas Smith.

Flemming Steen Jensen, EVP & Product Supply and Quality at Ascendis Pharma A/S, reported a sale of 19,460 ordinary shares.

Artisan Partners, through its various entities, has disclosed beneficial ownership of 4.2% of Ascendis Pharma A/S's ordinary shares as of June 30, 2026.

Janus Henderson Group plc has reported beneficial ownership of 3,719,452 American Depositary Shares, representing 6.0% of the class, in Ascendis Pharma A/S.

Capital International Investors has reported a 3.2% stake in Ascendis Pharma AS, holding 2,013,285 shares as of March 31, 2026.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 10.5% of Ascendis Pharma A/S - ADR.

T. Rowe Price Investment Management, Inc. has reported beneficial ownership of 9.9% of Ascendis Pharma A/S - ADR, holding 6,162,042 shares.

FMR LLC, through its subsidiaries, has disclosed beneficial ownership of 6.6% of Ascendis Pharma AS common stock as of March 31, 2026.